Literature DB >> 24980082

Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies.

Eder André Estracanholli1, Fabíola Silva Garcia Praça, Ana Beatriz Cintra, Maria Bernadete Riemma Pierre, Marilisa Guimarães Lara.   

Abstract

Liquid crystalline systems of monoolein/water could be a promising approach for the delivery of celecoxib (CXB) to the skin because these systems can sustain drug release, improve drug penetration into the skin layers and minimize side effects. This study evaluated the potential of these systems for the delivery of CXB into the skin based on in vitro drug release and skin permeation studies. The amount of CXB that permeated into and/or was retained in the skin was assayed using an HPLC method. Polarizing light microscopy studies showed that liquid crystalline systems of monoolein/water were formed in the presence of CXB, without any changes in the mesophases. The liquid crystalline systems decreased drug release when compared to control solution. Drug release was independent of the initial water content of the systems and CXB was released from cubic phase systems, irrespective of the initial water content. The systems released the CXB following zero-order release kinetics. In vitro drug permeation studies showed that cubic phase systems allowed drug permeation and retention in the skin layers. Cubic phase systems of monoolein/water may be promising vehicles for the delivery of CXB in/through the skin because it improved CXB skin permeation compared with the control solution.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24980082      PMCID: PMC4245435          DOI: 10.1208/s12249-014-0171-2

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  38 in total

1.  Phase behavior of a monoacylglycerol: (myverol 18-99K)/water system.

Authors:  J Clogston; J Rathman; D Tomasko; H Walker; M Caffrey
Journal:  Chem Phys Lipids       Date:  2000-10       Impact factor: 3.329

2.  Formulation of a drug delivery system based on a mixture of monoglycerides and triglycerides for use in the treatment of periodontal disease.

Authors:  T Norling; P Lading; S Engström; K Larsson; N Krog; S S Nissen
Journal:  J Clin Periodontol       Date:  1992-10       Impact factor: 8.728

Review 3.  Lyotropic liquid crystal systems in drug delivery.

Authors:  Chenyu Guo; Jun Wang; Fengliang Cao; Robert J Lee; Guangxi Zhai
Journal:  Drug Discov Today       Date:  2010-10-08       Impact factor: 7.851

4.  Nanostructured lipid carrier (NLC) based gel of celecoxib.

Authors:  Medha Joshi; Vandana Patravale
Journal:  Int J Pharm       Date:  2007-06-15       Impact factor: 5.875

5.  Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems.

Authors:  Ben J Boyd; Darryl V Whittaker; Shui-Mei Khoo; Greg Davey
Journal:  Int J Pharm       Date:  2006-01-04       Impact factor: 5.875

6.  Kinetics and mechanism of release from glyceryl monostearate-based implants: evaluation of release in a gel simulating in vivo implantation.

Authors:  S Allababidi; J C Shah
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

7.  Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion.

Authors:  N Subramanian; Saroj K Ghosal; S P Moulik
Journal:  Drug Dev Ind Pharm       Date:  2005-05       Impact factor: 3.225

8.  The in vitro release of some antimuscarinic drugs from monoolein/water lyotropic liquid crystalline gels.

Authors:  P B Geraghty; D Attwood; J H Collett; Y Dandiker
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

9.  Celecoxib determination in different layers of skin by a newly developed and validated HPLC-UV method.

Authors:  Fabíola Silva Garcia Praça; Maria Vitória Lopes Badra Bentley; Marilisa Guimarães Lara; Maria Bernadete Riemma Pierre
Journal:  Biomed Chromatogr       Date:  2011-02-10       Impact factor: 1.902

10.  Parameters affecting the drug release from in situ gelling nasal inserts.

Authors:  Ulrike Bertram; Roland Bodmeier
Journal:  Eur J Pharm Biopharm       Date:  2006-03-02       Impact factor: 5.571

View more
  6 in total

1.  Self-Assembled Cubic Liquid Crystalline Nanoparticles for Transdermal Delivery of Paeonol.

Authors:  Jian-Chun Li; Na Zhu; Jin-Xiu Zhu; Wen-Jing Zhang; Hong-Min Zhang; Qing-Qing Wang; Xiao-Xiang Wu; Xiu Wang; Jin Zhang; Ji-Fu Hao
Journal:  Med Sci Monit       Date:  2015-10-30

2.  Trans-resveratrol-loaded nonionic lamellar liquid-crystalline systems: structural, rheological, mechanical, textural, and bioadhesive characterization and evaluation of in vivo anti-inflammatory activity.

Authors:  Bruno Fonseca-Santos; Cínthia Yuka Satake; Giovana Maria Fioramonti Calixto; Aline Martins Dos Santos; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2017-09-14

Review 3.  Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals.

Authors:  Rajan Rajabalaya; Muhammad Nuh Musa; Nurolaini Kifli; Sheba R David
Journal:  Drug Des Devel Ther       Date:  2017-02-13       Impact factor: 4.162

4.  Pharmacokinetic and Pharmacodynamics of Self-Assembled Cubic Liquid Crystalline Nanoparticle Gel After Transdermal Administration.

Authors:  Na Zhu; Xiao-Xiang Wu; Yong Tian; Jin-Xiu Zhu; Jian-Chun Li
Journal:  Med Sci Monit       Date:  2018-04-18

Review 5.  Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms.

Authors:  Maria Chountoulesi; Stergios Pispas; Ioulia K Tseti; Costas Demetzos
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-31

6.  Papaverine hydrochloride containing nanostructured lyotropic liquid crystal formulation as a potential drug delivery system for the treatment of erectile dysfunction.

Authors:  Szilvia Berkó; Stella Zsikó; Gábor Deák; Attila Gácsi; Anita Kovács; Mária Budai-Szűcs; László Pajor; Zoltán Bajory; Erzsébet Csányi
Journal:  Drug Des Devel Ther       Date:  2018-09-12       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.